FDA Approved: KEPIVANCE — Supplemental Application (Swedish Orphan Biovitrum AB (publ))

View source ↗

Summary

FDA approved a supplemental labeling change for Kepivance (palifermin) submitted by Swedish Orphan Biovitrum AB (publ).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancies
• Oral Mucositis

Drugs mentioned

• Kepivance (Palifermin)

Snippet

SUPPL AP for KEPIVANCE (PALIFERMIN)